Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + Irinotecan in advanced gastric cancer
NCT01813253Phase 3Terminated
- Sponsor
- Kuhnil Pharmaceutical
- Start
- May 2013
- Primary completion
- Feb 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of nimotuzumab in gastric cancer (GC) and gastroesophageal junction cancer (2 arms), sponsored by Kuhnil Pharmaceutical. Primary endpoint: Overall Survival at 4.5 years. Started May 2013; status: terminated.
02
Drugs
nimotuzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT01813253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813253.